The invention provides anti-ETEC adhesin protein antibodies and methods of using the same.

A closed system is provided for enlarging viral and bacterial particles for identification by diffraction scanning. The closed system includes a transparent tube, a deformable dispenser, a quantity of first antibodies, a quantity of second antibodies, and a diffraction scanning device. The transparent tube contains the quantity of first antibodies, the quantity of second antibodies, and receives the exhaled air from an individual. The deformable dispenser drives the quantity of second antibodies to mix with a complex formed by target matter in the exhaled air and the quantity of first antibodies. The quantity of first antibodies interacts with the target matter. The quantity of second antibodies interacts with the complex formed by the target matter and the quantity of first antibodies. The diffraction scanning device measures the number and size of particles within the transparent tube.

Disclosed herein are methods of detecting microbial infection in mammalian subjects comprising treatment of a sample and detection of galactofuranose (galF)-containing antigenic components utilizing monoclonal antibodies. The methods disclosed provide for pretreatment of biological samples, such as urine samples, to maximize detection of galF antigens and improvement of sensitivity of galF antigen detection assays. The methods include minimizing intelectin-1 binding to galF antigens and improvement of monoclonal antibody binding. The detection methods are useful for identifying the presence of microbial antigens related to bacterial, fungal, and parasitic pathogens, including Streptococcus pneumoniae, Aspergillus species, Fusarium species, Coccidioides species, Cryptococcus species, Histoplasma species, and Leishmania species.

The present disclosure provides a biosignature that distinguishes Lyme disease, including early Lyme disease, from STARI. The present disclosure also provides methods for detecting Lyme disease and STARI, as well as methods for treating subjects diagnosed with Lyme disease or STARI.

In one aspect the invention provides a method for distinguishing between a viral-only infection of the upper respiratory tract or a bacterial or viral/bacterial coinfection in a patient by analyzing a respiratory sample.

The present disclosure relates to a method of diagnosing Lyme disease in a subject comprising measuring the level of B. burgdorferi peptidoglycan or the level of an antibody that specifically binds to B. burgdorferi peptidoglycan (“anti-peptidoglycan agent”). The present disclosure also relates to a method of treating a Lyme disease in a subject in need thereof comprising administering to the subject an antagonist against B. burgdorferi peptidoglycan (e.g., an anti-peptidoglycan antibody or a peptidoglycan-specific hydrolase). Antagonists (e.g., anti-peptidoglycan antibodies) suitable for the present methods are also disclosed.

A single unit, handheld field portable apparatus and method for analyzing Ochratoxin A (OTA) in rice quality monitoring, based on fluorescence signal output. Aliquots may be analyzed by adding at least one or more reagents to the sample aliquot that reacts selectively with an analyte contained therein. The reaction product, which is selective for the analyte of interest and proportional to its concentration, is measured with an appropriate detector. This enables simple and accurate testing of samples using time honored wet-chemical analysis method in microliter volume regimes while producing remarkably small volumes of waste. The device includes a multipurpose controller board for processing and analysis purpose, a camera which is integrated with the controller, a resistive touch liquid crystal display to view the results, a light emitting diode to emit the UV light, and a power bank. The device may operate using a touch display.

A biorecognition element for rapid detection of fuel biocontamination. The biorecognition element is a biorecognition element selected from SEQ. ID No. 2 through SEQ. ID No. 24, SEQ. ID No. 22 through SEQ. ID No. 44, SEQ. ID No. 46 through SEQ. ID No. 57, SEQ. ID No. 59 through SEQ. ID No. 196 or SEQ. ID No. 198 through SEQ. ID No. 332.

The present invention provides methods and systems to accurately detect and measure levels of endogenous antibodies, for examples endogenous IgA, to particular antigens in a biological sample from a companion animal, which is useful to diagnose inflammatory conditions, including bowel disease (IBD), gastrointestinal infections, and food sensitivities in companion animals, e.g., dogs or cats, and to distinguish among such gastrointestinal disorders. Such methods and systems identify whether a sample from the patient is associated with an inflammatory condition, infection, and/or food sensitivity condition, by using non-invasive means, thus conveniently providing information useful for guiding treatment decisions.

Systems, surrogates, indicators and methods for rapid assessment of sanitation processes are provided. Non-living and non-toxic surrogates applied to a platform or encapsulated in a biological material mounted to a platform are exposed to a sanitation process to be evaluated. Responses to sanitation are measured and quantified using FTIR and chemometrics including principal component analysis (PCA), partial least squares regression (PLSR), loading plots and predictive models. An artificial leaf platform with one or more types of surrogates on one surface and an anchor such as an adhesive film on a second surface is described. Surrogate types include nucleic acid, phage, yeast and algae surrogates. Surrogates may also be attached directly or through a polymer to the platform surface. Surrogates may also be encapsulated or attached to the outside of a biological carrier such as a yeast cell that is free or coupled to the platform.